There have recently been a number of major drug approvals for the treatment of acute lymphoblastic leukemia (ALL). One such approval was that of blinatumomab based on data from pivotal studies, including the Phase III TOWER study (NCT02013167) and the Phase II ALCANTARA trial (NCT02000427). Here, Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses key data on this drug, highlighting MRD status, in addition to what we know about the setting and type of patient where the drug is most beneficial. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Novel ALL treatment strategies: blinatumomab
